Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk RalliedInvestors Business Daily • 11/26/25
Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's preventionReuters • 11/25/25
Novo Nordisk Signals 2026 Push After Amycretin Posts Major Phase 2 Gains In Type 2 Diabetes PatientsBenzinga • 11/25/25
Novo Nordisk Stock Jumps on Positive Weight-Loss Drug Data. Why It Deserves Better.Barrons • 11/25/25
Novo Nordisk's Longshot Alzheimer's Trial Didn't Work, But It Is Still Worth BuyingSeeking Alpha • 11/25/25
Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetesGlobeNewsWire • 11/25/25
Novo Nordisk Faces Setback. Here's What Caused the Ozempic Maker's Stock to Tumble Monday.Investopedia • 11/24/25